BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/22/2014 5:28:00 PM | Browse: 1052 | Download: 753
Publication Name World Journal of Clinical Oncology
Manuscript ID 9658
Country/Territory United Kingdom
Received
2014-02-28 14:26
Peer-Review Started
2014-03-06 11:29
To Make the First Decision
2014-03-26 15:15
Return for Revision
2014-03-31 15:50
Revised
2014-04-20 22:15
Second Decision
2014-06-11 13:28
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-06-11 13:44
Articles in Press
2014-06-11 13:44
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2014-07-21 16:09
Publish the Manuscript Online
2014-08-01 15:17
ISSN 2218-4333 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Minireviews
Article Title Pleomorphic lobular carcinoma in situ of the breast: Can the evidence guide practice?
Manuscript Source Invited Manuscript
All Author List Andrew Pieri, James Harvey and Nigel Bundred
Funding Agency and Grant Number
Corresponding Author Nigel Bundred, MD, FRCS, Professor of Surgical Oncology, Nightingale Centre, University Hospital of South Manchester, Wythenshawe Hospital, Southmoor Road, Manchester, M23 9LT, United Kingdom. nigel.j.bundred@manchester.ac.uk
Key Words Pleomorphic lobular carcinoma in situ; Breast cancer; Breast carcinoma; Carcinoma in situ; Guideline; Excision margin; Recurrence rate
Core Tip Pleomorphic lobular carcinoma in situ (PLCIS) is a breast lesion, the clinical significance of which is a subject of controversy. To date, this systematic review is the largest pooled series of clinical data regarding PLCIS. We aimed to establish whether current guidelines for management are consistent with the evidence. The results demonstrate a lack of high quality data and guidelines for management are variable. Analysis revealed a high incidence of concurrent invasive disease with PLCIS (49%) and following excision, a recurrence rate of 9.4%. We conclude that it would seem prudent to manage PLCIS as with ductal carcinoma in situ, although there is a dire need for long-term outcome studies.
Publish Date 2014-08-01 15:17
Citation Pieri A, Harvey J, Bundred N. Pleomorphic lobular carcinoma in situ of the breast: Can the evidence guide practice? World J Clin Oncol 2014; 5(3): 546-553
URL http://www.wjgnet.com/2218-4333/full/v5/i3/546.htm
DOI http://dx.doi.org/10.5306/wjco.v5.i3.546
Full Article (PDF) WJCO-5-546.pdf
Full Article (Word) WJCO-5-546.doc
Manuscript File 9658-Review.docx
Answering Reviewers 9658-Answering reviewers.pdf
Copyright License Agreement 9658-Copyright assignment.pdf
Peer-review Report 9658-Peer review(s).pdf
Scientific Misconduct Check 9658-CrossCheck.jpg
Scientific Editor Work List 9658-Scientific editor work list.pdf